Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/29/2026

1. MDB
2. SPY
3. MTN
4. AIR
5. FFAI
6. JEF
7. KMX
8. META
9. AMD
10. SPCX

Go back to Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Amgen Inc (NASDAQ: AMGN) Delayed: 418.34 +0.21 (0.05%)
Previous Close $418.13    52 Week High $176.85 
Open $414.37    52 Week Low $133.64 
Day High $421.46    P/E 63.00 
Day Low $414.11    EPS $6.64 
Volume 905,946